Anastasia Uster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasia Uster has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Anita M. Hennige
Boehringer Ingelheim International GmbH Biberach Germany
1 shared publicationAnna Rita Mazo
Boehringer Ingelheim International GmbH, Ingelheim-am-Rhein, Germany
1 shared publication- Carel Wynand le Roux
University College Dublin, Dublin, Ireland
1 shared publication - Carl Alexander Roberts
Department of Psychology, Institute of Population Health, University of Liverpool, Liverpool, L69 7ZB, UK
1 shared publication - Donald M. Bushnell
PPD Evidera Patient Centered Research, Thermo Fisher Scientific
1 shared publication Egon Pfarr
Boehringer Ingelheim International GmbH, Ingelheim-am-Rhein, Germany
1 shared publication
Latest Publications
- Open Access
- 5 October 2025
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (12) , 1091-1096
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial
- 5 October 2025
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (12) , 1091-1096
Open AccessEmpagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial
- Open Access
Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight
Objective: The objective of this study was to develop a measure of eating behaviors in adults living with obesity or overweight.Methods: Based on concept‐elicitation (n = 53) and cognitive‐debriefing (n = 15) studies, a draft eating behavior patient‐reported outcome (EB PRO) measure was developed. Its psychometric properties were established using data from a 46‐week clinical trial of an investigational antiobesity medication (n = 387).Results: The final EB PRO comprised 12 items across two domains (i.e., “Desire to Eat” and “Capacity to Resist”; 6 items each) and a Total Eating Behavior score (0–48; higher scores worse). The EB PRO demonstrated good test–retest reliability (intraclass correlation coefficients > 0.7). Confirmatory factor analysis showed a comparative fit index of 0.98 with good internal consistency (Cronbach α > 0.7). The EB PRO generally exhibited moderate‐to‐large correlations with the Patient Global Impression of Severity questionnaire and Three‐Factor Eating Questionnaire and weaker correlation with the 36‐Item Short‐Form Health Survey version 2 Physical Functioning scale. All EB PRO scores improved from baseline to week 46 (p < 0.0001), demonstrating sensitivity to change with therapy. Clinically meaningful thresholds were defined as eight‐ and four‐point changes in Total Eating Behavior and domain scores, respectively.Conclusions: The EB PRO measure is a promising tool for assessing eating behaviors in people with obesity or overweight.
Open AccessDevelopment and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight
Objective: The objective of this study was to develop a measure of eating behaviors in adults living with obesity or overweight.Methods: Based on concept‐elicitation (n = 53) and cognitive‐debriefing (n = 15) studies, a draft eating behavior patient‐reported outcome (EB PRO) measure was developed. Its psychometric properties were established using data from a 46‐week clinical trial of an investigational antiobesity medication (n = 387).Results: The final EB PRO comprised 12 items across two domains (i.e., “Desire to Eat” and “Capacity to Resist”; 6 items each) and a Total Eating Behavior score (0–48; higher scores worse). The EB PRO demonstrated good test–retest reliability (intraclass correlation coefficients > 0.7). Confirmatory factor analysis showed a comparative fit index of 0.98 with good internal consistency (Cronbach α > 0.7). The EB PRO generally exhibited moderate‐to‐large correlations with the Patient Global Impression of Severity questionnaire and Three‐Factor Eating Questionnaire and weaker correlation with the 36‐Item Short‐Form Health Survey version 2 Physical Functioning scale. All EB PRO scores improved from baseline to week 46 (p < 0.0001), demonstrating sensitivity to change with therapy. Clinically meaningful thresholds were defined as eight‐ and four‐point changes in Total Eating Behavior and domain scores, respectively.Conclusions: The EB PRO measure is a promising tool for assessing eating behaviors in people with obesity or overweight.